Prospective use of the single-mouse experimental design for the evaluation of PLX038A

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

(2019) Jason Fangusaro et al.   LANCET ONCOLOGY

Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft

(2019) Shaun D. Fontaine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

(2019) Jo Lynne Rokita et al.   Cell Reports

Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients

(2018) E. Palmerini et al.   ACTA ONCOLOGICA

The landscape of genomic alterations across childhood cancers

(2018) Susanne N. Gröbner et al.   NATURE

Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours

(2018) Xiaotu Ma et al.   NATURE

Complete Remission of an Extra-Cranially Disseminated Anaplastic Pleomorphic Xanthoastrocytoma (A-PXA) with Everolimus: A Case Report and Literature Review

(2018) Amanda J. Saraf et al.   PEDIATRIC NEUROLOGY

Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children’s Oncology Group Randomized ACNS0332 Trial

(2018) Eugene I. Hwang et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic

(2017) Loujin Houdaihed et al.   MOLECULAR PHARMACEUTICS

A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

(2017) Anuradha Banerjee et al.   NEURO-ONCOLOGY

Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

(2017) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-Raf Inhibition in the Clinic: Present and Future

(2016) Warren Fiskus et al.   Annual Review of Medicine

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis

(2016) Brendan Murphy et al.   CANCER RESEARCH

Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group

(2016) Ariadne H.A.G. Ooms et al.   CLINICAL CANCER RESEARCH

Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes

(2016) Kurtulus Gokduman   CURRENT DRUG TARGETS

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2016) Brenda J. Weigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

(2015) Kristian W. Pajtler et al.   CANCER CELL

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

(2014) A. Oberthuer et al.   CLINICAL CANCER RESEARCH

Macromolecular Prodrug That Provides the Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax , and Low Glucuronide Formation

(2014) Daniel V. Santi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeted treatment for sonic hedgehog-dependent medulloblastoma

(2014) M. W. Kieran   NEURO-ONCOLOGY

Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors

(2014) J. F. Shern et al.   Cancer Discovery

The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation

(2014) Andrew S. Brohl et al.   PLoS Genetics

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

(2013) F. Lin et al.   CLINICAL CANCER RESEARCH

Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma

(2013) E Sokolowski et al.   ONCOGENE

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

(2012) Marcel Kool et al.   ACTA NEUROPATHOLOGICA

Molecular subgroups of medulloblastoma

(2012) Paul A Northcott et al.   Expert Review of Neurotherapeutics

Macromolecular therapeutics in cancer treatment: The EPR effect and beyond

(2012) Hiroshi Maeda   JOURNAL OF CONTROLLED RELEASE

Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates

(2012) D. V. Santi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers

(2011) Craig H Mermel et al.   GENOME BIOLOGY

Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma

(2010) André Oberthuer et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program

(2010) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors

(2009) Wayne L. Furman et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE